drugset / Trial / NCT02989558

A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI

NCT02989558

Phase 3 Completed 90 enrolled University of Athens
RandomizedParallel-groupOpen-labelPrevention

Summary

Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization in the cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and 30 days afterwards, than Clopidogrel plus ASA. This hypothesis will be investigated by measuring the number of High Intensity Transient Signals (HITS) as assessed with transcranial Doppler (TCD) on middle cerebral arteries.

Timeline

Start
2016-12
Primary completion
2020-02-01
Completion
2021-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg
Comparator Ticagrelor Small molecule 90 mg
Comparator Aspirin Small molecule 80 mg

Indications